Alfredo Viray Chua, Jr.

Dr. Alfredo Viray Chua, Jr.


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Integrative Cancer Therapies
Verified
Journal Article
Open access
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
AHAylmer Rex B. Hernandez
Aylmer Rex B. Hernandez
MMMarvin Jonne L. Mendoza
Marvin Jonne L. Mendoza
MJMichael D. San Juan
Michael D. San Juan
Background: Cancer cachexia is a common debilitating weight loss syndrome in advanced cancer, particularly lung cancer. Omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, with their immune-modulating effects, have been used to improve the nutritional status of patients with cancer cachexia. Aim: Evaluate the effects of omega-3 fatty acids in change in weight and lean body/skeletal mass, and health-related quality of life scores (HRQoL) in patients with advanced non-small cell lung cancer and cancer cachexia. Design and Data Sources: Clinical trials from electronic databases and unpublished literature (date of last search 20 December 2023) were independently reviewed and evaluated by authors for their methodological quality. Data from eligible trials were extracted and analyzed in a meta-analysis. Results: Six trials were included. Five trials (354 patients) assessed change in weight; 2 trials (132 patients) assessed change in lean body/skeletal mass and HRQoL scores (Global Health and Physical Functioning subscales). There is a significant difference in change in weight (mean difference [MD]: 1.22, 95% CI: 1.05-1.38, P < .01) and HRQoL scores (Global Health [MD: 14.40, 95% CI: 9.22-19.59, P < .01] and Physical Functioning [MD: 10.38, 95% CI: 8.50-12.27, P < .01] subscales) favoring the omega-3 fatty acids group. The change in lean body/skeletal mass is not significant (MD: 2.05, 95% CI: −0.55 to 4.66, P = .12). Conclusions: Among patients with advanced non-small cell lung cancer and cancer cachexia, supplementation with omega-3 fatty acids leads to a significant increase in weight and HRQoL scores but not in change in lean body/skeletal mass.

6 June 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
HSHaiyang Sheng
Haiyang Sheng
ELEmily Liang
Emily Liang
SGShipra Gandhi
Shipra Gandhi
MKMarilyn L Kwan
Marilyn L Kwan
SYSong Yao
Song Yao
Background: Relatively little is known about the differences in prognostic factors for early vs late recurrence among women with early stage estrogen receptor–positive breast cancer. Methods: We analyzed factors related to early (<5 years) vs late (≥5 years) recurrence in 2992 women with stage I-IIB estrogen receptor–positive breast cancer in the Pathways Study, a prospective cohort of women with breast cancer enrolled between 2006 and 2013, with ascertainment of recurrence and death through December 2021. Results: After a median follow-up of 13.3 years, 341 (13.8%) women had recurrences, including 181 (53.7%) with late recurrence. Higher stage and grade were associated with recurrence regardless of timing, whereas progesterone receptor negativity was associated with early but not late recurrence. Receipt of endocrine therapy was associated with reduced risk of overall recurrence, but the length of endocrine therapy was not statistically significant in multivariable models. Minoritized racial and ethnic groups, including Asian, Black, and Hispanic women, had higher risk of early but not late recurrence compared to non-Hispanic White women. The trend of higher risk of early recurrence among these groups remained after adjustment for clinical, demographic, and socioeconomic factors but was statistically significant only in Asian women. Conclusions: Our study revealed potentially important distinctions for early vs late recurrence, including the associations with progesterone receptor negativity and self-identified race and ethnicity. Possible higher risk of early recurrence among Asian, Black, and Hispanic women provides novel evidence for the existence of disparities in cancer outcomes, even within the breast cancer subtype indicative of generally good prognosis.

1 March 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
JDJennifer Delmerico
Jennifer Delmerico
HSHaiyang Sheng
Haiyang Sheng
XHXin-Wei Huang
Xin-Wei Huang
ELEmily Liang
Emily Liang
SYSong Yao
Song Yao
PURPOSE: Minoritized racial/ethnic groups are historically under-represented in cancer clinical trials, which may be exacerbated in recent trials on immune checkpoint inhibitors (ICIs). We examined the representation and reporting of the racial/ethnic composition of participants in clinical trials on ICIs. METHODS: We examined English full-text trials on ICIs published from 2007 to 2022. Information on trial characteristics and racial/ethnic composition of participants was extracted from published papers or ClinicalTrials.gov. Differences in participation by publication year, ICI agent, and cancer site were analyzed. Enrollment-incidence ratio (EIR) was calculated to compare the proportion of minoritized racial/ethnic group patients in US-based trials against age-adjusted cancer incidence data available for the US population. An EIR > 1 signified over-representation, whereas an EIR <1 signified under-representation. RESULTS: Of the 471 trials examined, racial composition was unreported in 146 (31%), whereas Hispanic/Latinx ethnicity was unreported in 278 (59%). Only 30 (6%) trials reported race/ethnicity-specific results. In US-only trials (n = 174), White patients were over-represented (EIR, 1.20 [95% CI, 1.17 to 1.22]), whereas Hispanic/Latinx patients were the most under-represented (EIR, 0.35 [95% CI, 0.24 to 0.48]), followed by Black/African American patients (EIR, 0.66 [95% CI, 0.54 to 0.79]). Subgroup analyses consistently indicated over-representation of White patients across publication years (EIR, 1.19-1.24), ICI classes (EIR, 1.16-1.23), and cancer sites (EIR, 1.11-1.31), whereas Hispanic/Latinx patients were consistently under-represented. An upward trend of trial representation and reporting was observed for all minoritized racial/ethnic groups over time (trend P values ≤.05). CONCLUSION: Disparities in the representation and reporting of minoritized racial/ethnic groups persist in recent trials on ICIs, necessitating collaborative efforts for improved diversity and equitable cancer treatment access.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
LCLance Isidore Catedral
Lance Isidore Catedral
HTHarold Nathan Tan
Harold Nathan Tan
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
DSDanielle Benedict Sacdalan
Danielle Benedict Sacdalan
DSDennis Sacdalan
Dennis Sacdalan
PURPOSE: Several factors affect how medical oncologists in the Philippines use biomarkers in real-world practice. This study describes patterns of biomarker testing for the management of breast, colorectal, and lung cancers among medical oncologists in the Philippines. METHODS: A cross-sectional survey was performed among practicing medical oncologists in the Philippines from November to December 2019. The questionnaire determined the ideal and practical use of biomarkers as perceived by the respondents. Responses were summarized. Associations between biomarker use across select conditions were determined. RESULTS: A total of 127 respondents (38% of medical oncologists in the Philippines) participated in this study. In actual practice, 97% of the respondents requested estrogen receptor/progesterone receptor testing, and 93% requested human epidermal growth factor receptor 2 testing. For colorectal cancer, the respondents would use KRAS and mismatch repair/microsatellite instability, but 59.84% had never used BRAF. For lung cancer, 97.64% of respondents would test for epidermal growth factor receptor ( EGFR), 88.19% would test for PD-L1, 80.31% for anaplastic lymphoma kinase, 58.27% for ROS1, and 33.07% for BRAF. In actual practice, EGFR was the most frequently ordered test (67.72%), while 44.80% of medical oncologists had never used ROS1. The most common reason for testing was adherence to international guidelines (96%). The most commonly cited barrier to biomarker use was patients’ financial constraints (94.49%). Overall, the respondents’ use of biomarkers was not significantly associated with institutional affiliation, the number of patients they saw monthly, and the availability of biomarker tests in their areas of practice. CONCLUSION: Medical oncologists in the Philippines would use biomarkers in treating breast, colorectal, and lung cancers if these were clinically indicated and if cost were not a factor. Financial difficulty experienced by patients was the most commonly cited barrier to biomarker use.

5 June 2020 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
MMMarvin Jonne Mendoza
Marvin Jonne Mendoza
MAMark Ando
Mark Ando
CPCyril Jonas Planilla
Cyril Jonas Planilla
GFGracieux Fernando
Gracieux Fernando
JIJorge Ignacio
Jorge Ignacio

15 June 2020 in ecancermedicalscience
Verified
Journal Article
Open access
LLLouis Mervyn B Leones
Louis Mervyn B Leones
CBCarlo Miguel P B Berba
Carlo Miguel P B Berba
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
JSJennifer Sandoval-Tan
Jennifer Sandoval-Tan
Caring for the carers: safeguarding oncologists’ mental health in the time of COVID-19 Louis Mervyn B Leonesa, Carlo Miguel P Berbab, Alfredo V Chu